Aquestive Therapeutics, Inc. (NASDAQ:AQST) Expected to Announce Earnings of -$0.45 Per Share

Wall Street analysts predict that Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) will announce ($0.45) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aquestive Therapeutics’ earnings, with estimates ranging from ($0.46) to ($0.44). Aquestive Therapeutics posted earnings of ($0.41) per share during the same quarter last year, which would suggest a negative year over year growth rate of 9.8%. The company is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Aquestive Therapeutics will report full year earnings of ($1.65) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.41). For the next financial year, analysts anticipate that the business will post earnings of ($0.68) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Aquestive Therapeutics.

Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last posted its earnings results on Tuesday, March 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). The firm had revenue of $11.08 million for the quarter, compared to analysts’ expectations of $9.81 million. During the same quarter in the previous year, the business posted ($0.60) EPS.

Several equities analysts recently commented on AQST shares. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Aquestive Therapeutics in a report on Thursday, December 23rd. Wedbush cut their price target on shares of Aquestive Therapeutics from $26.00 to $8.00 and set an “outperform” rating on the stock in a report on Thursday, March 10th. Finally, Zacks Investment Research upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a report on Monday.

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. grew its stake in Aquestive Therapeutics by 5.3% in the 4th quarter. BlackRock Inc. now owns 348,366 shares of the company’s stock worth $1,354,000 after acquiring an additional 17,420 shares in the last quarter. Virtu Financial LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth about $308,000. Schonfeld Strategic Advisors LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth about $411,000. Millennium Management LLC grew its stake in Aquestive Therapeutics by 10.8% in the 4th quarter. Millennium Management LLC now owns 358,875 shares of the company’s stock worth $1,396,000 after acquiring an additional 35,101 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Aquestive Therapeutics in the 4th quarter worth approximately $116,000. Institutional investors and hedge funds own 39.17% of the company’s stock.

Shares of NASDAQ:AQST opened at $2.22 on Monday. The company has a market capitalization of $92.06 million, a price-to-earnings ratio of -1.21 and a beta of 3.30. Aquestive Therapeutics has a 12 month low of $2.02 and a 12 month high of $6.40. The firm’s 50-day moving average is $2.62 and its 200 day moving average is $3.89.

Aquestive Therapeutics Company Profile (Get Rating)

Aquestive Therapeutics, Inc engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

See Also